| REV-ERBα Protein | |
|---|---|
| Protein Name | REV-ERBα (Nuclear Receptor Subfamily 1 Group D Member 1) |
| Gene | [NR1D1](/genes/nr1d1) |
| UniProt ID | [Q9UH73](https://www.uniprot.org/uniprot/Q9UH73) |
| PDB ID | 3o0p, 5t0j |
| Molecular Weight | 48 kDa |
| Subcellular Localization | Nucleus |
| Protein Family | Nuclear receptor, NR1 subfamily |
| Aliases | NR1D1, RVR, THRA1, BD73 |
| Brain Expression | Suprachiasmatic nucleus, [hippocampus](/brain-regions/hippocampus), [cortex](/brain-regions/cortex), striatum |
REV-ERBα (Nuclear Receptor Subfamily 1 Group D Member 1, encoded by NR1D1) is a nuclear receptor that functions as a transcriptional repressor and plays a central role in the mammalian circadian clock [1]. Unlike classical nuclear receptors that require ligand binding for activation, REV-ERBα is regulated primarily at the transcriptional level by the core clock machinery and exhibits robust circadian oscillations. This page describes its structure, normal function in the nervous system, role in neurodegenerative diseases, and therapeutic potential.
REV-ERBα contains the typical nuclear receptor domain architecture:
The LBD of REV-ERBα binds heme with nanomolar affinity, which stabilizes the repressive conformation and enhances recruitment of co-repressor proteins including NCoR (Nuclear Receptor Co-Repressor) and HDAC3 (Histone Deacetylase 3) [2].
REV-ERBα is a core component of the negative feedback loop in the circadian clock:
This ~24-hour oscillation drives circadian expression of hundreds of genes involved in metabolism, sleep, and cellular function.
In the brain, REV-ERBα regulates:
REV-REBα is also expressed in:
REV-ERBα has emerged as a potential therapeutic target in Alzheimer's disease:
Amyloid Pathology: Studies show that REV-ERBα activation reduces amyloid-β production:
Circadian Disruption: AD patients commonly exhibit circadian rhythm disturbances:
Neuroinflammation: REV-ERBα activation suppresses microglial activation:
In Parkinson's disease, REV-ERBα shows protective effects:
Dopaminergic Neuron Survival: REV-ERB agonists protect substantia nigra pars compacta neurons:
Neuroinflammation: Microglial REV-ERBα activation reduces dopaminergic neuron loss:
α-Synuclein Pathology: Evidence suggests REV-ERBα may affect α-synuclein aggregation:
Multiple Sclerosis: REV-ERB agonists show promise in MS models:
Amyotrophic Lateral Sclerosis (ALS):
Huntington's Disease:
REV-ERBα interacts with several key proteins:
| Protein | Interaction Type | Functional Consequence |
|---|---|---|
| BMAL1 | Transcriptional regulation | Core clock feedback loop |
| CLOCK | Heterodimer partner | Transcriptional activation |
| NCoR1/2 | Co-repressor recruitment | Gene repression |
| HDAC3 | Histone deacetylation | Chromatin compaction |
| Heme | Ligand binding | Conformational stabilization |
| PER2 | Transcriptional co-repressor | Enhanced repression |
| CRY1/2 | Transcriptional repression | Core clock regulation |
| PGC-1α | Co-activator recruitment | Metabolic gene regulation |
| NF-κB p65 | Cross-talk | Inflammation regulation |
Synthetic REV-ERB agonists have been developed:
These compounds show neuroprotective effects in multiple models.
REV-ERB targeting offers several therapeutic opportunities:
Nr1d1 Knockout Mice:
Transgenic Overexpression:
REV-ERBα is a nuclear receptor that serves as a core component of the circadian clock and regulates genes involved in metabolism, inflammation, and neuronal function. Its dysregulation contributes to neurodegenerative disease pathogenesis, while pharmacological activation shows promise for neuroprotection. The development of brain-penetrant REV-ERB agonists represents a novel therapeutic approach for Alzheimer's disease, Parkinson's disease, and related conditions.
REV-ERBα: a nuclear receptor integrator of circadian rhythms and metabolism (Eckel-Mahan & Sassone-Corsi, 2013). 2013. ↩︎
Heme binding by the nuclear receptor REV-ERBα modulates circadian repression (Yin et al. 2007). 2007. ↩︎
Circadian nuclear receptor REV-ERBα regulates inflammatory responses in microglia (Griffin et al. 2019). 2019. ↩︎
Pharmacological activation of REV-ERBα improves cognition and reduces amyloid pathology in AD mouse models (Sulli et al. 2018). 2018. ↩︎
REV-ERBα agonist SR9009 protects dopaminergic neurons in Parkinson's disease models (Chen et al. 2020). 2020. ↩︎
REV-ERBα as a therapeutic target in neurodegenerative diseases (Burr et al. 2021). 2021. ↩︎